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Background: The most recommended NRTI combinations as first-line antiretroviral treatment for HIV-1 infection in
resource-rich settings are tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine.
Efficacy studies of these combinations also considering pill numbers, dosing frequencies and ethnicities are rare.
Methods:We included patients starting first-line combination ART (cART) with or switching from first-line cART without
treatment failure to tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine
plus efavirenz or nevirapine. Cox proportional hazards regression was used to investigate the effect of the different
NRTI combinations on two primary outcomes: virological failure (VF) and emergence of NRTI resistance.
Additionally, we performed a pill burden analysis and adjusted the model for pill number and dosing frequency.
Results: Failure events per treated patient for the four NRTI combinations were as follows: 19/1858 (tenofovir/
emtricitabine), 9/387 (abacavir/lamivudine), 11/344 (tenofovir/lamivudine) and 45/1244 (zidovudine/lamivudine).
Compared with tenofovir/emtricitabine, abacavir/lamivudine had an adjusted HR for having VF of 2.01 (95% CI
0.86–4.55), tenofovir/lamivudine 2.89 (1.22–6.88) and zidovudine/lamivudine 2.28 (1.01–5.14), whereas for the
emergence of NRTI resistance abacavir/lamivudine had an HR of 1.17 (0.11–12.2), tenofovir/lamivudine
11.3 (2.34–55.3) and zidovudine/lamivudine 4.02 (0.78–20.7). Differences among regimens disappeared when
models were additionally adjusted for pill burden. However, non-white patients compared with white patients
and higher pill number per day were associated with increased risks of VF and emergence of NRTI resistance: HR
of non-white ethnicity for VF was 2.85 (1.64–4.96) and for NRTI resistance 3.54 (1.20–10.4); HR of pill burden for VF
was 1.41 (1.01–1.96) and for NRTI resistance 1.72 (0.97–3.02).
Conclusions:Although VFand emergence of resistance was very low in the population studied, tenofovir/emtricitabine
appears to be superior to abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. However, it is unclear
whether these differences are due to the substances as such or to an association of tenofovir/emtricitabine regimens
with lower pill burden.
Introduction
More than 25 antiretroviral drugs from 6 different drug classes
against HIV-1 infection are available today. The standard
combination ART (cART) consists of two NRTIs and a potent
third agent, e.g. an NNRTI.1 Recent guidelines recommend tenofo-
vir/emtricitabine or abacavir/lamivudine in combination with
either efavirenz or nevirapine, or rilpivirine for individuals with
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HIV-1-RNA ,100000 copies/mL as the preferred NRTI backbone
for first-line cART including NNRTI.1,2 Alternatively, if unavailability
or intolerance exists, tenofovir/lamivudine and zidovudine/lamiv-
udine are recommended.3,4 These were used in first-line regimens
before the availability of tenofovir/emtricitabine and abacavir/
lamivudine as fixed-dose combinations and are still widely used
in resource-limited settings.
Studies directly comparing all these four NRTI combinations in
large populations are lacking and the relative in vivo efficacy is
unclear. Zidovudine/lamivudine showed similar potency as tenofo-
vir/emtricitabine plus efavirenz in a randomized controlled trial,5 but
is no longer a first-line option due to toxicity6 and twice-daily dos-
ing.7 Although abacavir/lamivudine and tenofovir/emtricitabine
were found to provide comparable antiretroviral efficacy as first-line
treatment in a randomized trial,8 in another clinical trial abacavir/
lamivudine showed inferior virological responses compared
with tenofovir/emtricitabine in patients with baseline HIV-RNA
levels .100000 copies/mL9,10 and abacavir/lamivudine was also
associated with more adverse events including lipid abnormal-
ities.10 Moreover, some randomized trials observed better virological
responses for regimens containing tenofovir/emtricitabine than
tenofovir/lamivudine,11 whereas other studies12,13 observed equal
suppression rates. A recent observational study comparing treat-
ment-naive patients initiating tenofovir/lamivudine or tenofovir/
emtricitabine plus an NNRTI found that tenofovir/lamivudine led to
more virological failures (VFs); however, this study did not consider
adherence, pill counts or dosing frequency as potential confounders.14
Comparing NRTI backbones is a complex undertaking because
they are formulated differentially: for tenofovir/emtricitabine and
abacavir/lamivudine once daily and for zidovudine/lamivudine
twice daily fixed-dose combinations exist. Efavirenz can be given
in combination with tenofovir/emtricitabine, but is mostly used as
a single-tablet regimen including efavirenz/tenofovir/emtricita-
bine. In addition, lamivudine can be taken once or twice daily in
contrast to emtricitabine, which has exclusively the once-daily
option. Thus, the daily number of total pills and the maximal dos-
ing frequency can vary substantially among zidovudine, abacavir,
emtricitabine, lamivudine and tenofovir in NNRTI-containing regi-
mens. Randomized clinical trials mostly compare just two back-
bones. They do not necessarily reflect a routine clinical setting
because patients are often highly selected due to strict enrolment
criteria and men are enrolled over-proportionally in general.
However, it is important to examine the treatment efficacy of
NRTI backbones with regard to pill burden and dosing frequency,
since governments, health insurers and third-party payers may
soon start to put pressure on using also non-coformulated ART
generics in the future due to considerably lower prices.
The aim of this study was to compare tenofovir/emtricitabine,
abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamiv-
udine paired with efavirenz or nevirapine as first-line cART regard-
ing virological responses and emergence of NRTI resistance in the
representative Swiss HIV Cohort Study (SHCS) and to evaluate the
impact of pill burden and dosing frequency on treatment efficacy.
Methods
Selection of patients
Our analysis was based on ART-experienced patients from the SHCS start-
ing treatment up to 8 January 2014. The SHCS, continuously enrolling
patients aged 16 or older since 1988, is a prospective and nationwide
cohort study including a biobank. The SHCS is representative of the HIV epi-
demic in Switzerland; it includes at least 53% of all HIV cases ever diag-
nosed in Switzerland, 72% of all patients receiving ART and 69% of the
nationwide registered AIDS cases.15 Local ethics committees have
approved the SHCS for all participating institutions and written informed
consent was obtained from all patients.15,16
Resistance data are generated from routine clinical testing performed by
four laboratories authorized by the Swiss Federal Office of Public Health. All
laboratories sequenced the full protease gene and at least codons 28–225
of the reverse transcriptase gene using population-based sequencing with
commercial assays (Viroseq Vs.1, PE Biosystems; Viroseq Vs. 2, Abbott AG;
VircoTYPE HIV-1 Assay, Virco Lab) or in-house methods.17 They all partici-
pate in the annual quality control evaluation by the Agence Nationale de
la Recherche sur le SIDA et les he´patites virales (ANRS) since 2002. All
sequences are entered into the SHCS drug-resistance database using
SmartGene’s Integrated Database Network System (SmartGene, Zug,
Switzerland, IDNS version 3.6.3).18 Additionally, we systematically selected
and retrospectively sequenced plasma samples from treatment-naive and
treatment-failing patients stored in our biobank, especially for samples
obtained before routine genotyping was introduced in 2002.
To compare the efficacy of the different NRTI backbones (tenofovir/
emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovu-
dine/lamivudine) combined with either efavirenz or nevirapine, we identi-
fied HIV-1-infected patients from the SHCS who had initiated their first
cART with one of the regimens mentioned above or switched from their
first cART to one of these regimens for reasons other than treatment fail-
ure. Patients were excluded from the analysis if baseline resistance was
identified according to the Stanford database algorithm (mutation penalty
score ≥15, Stanford genotypic resistance interpretation algorithm version
7.0: http://sierra2.stanford.edu/sierra/servlet/JSierra).
Furthermore, we assessed tablet usage for pill burden analysis, i.e.
whether the three drugs in a regimen were prescribed separately or com-
bined. Patients without complete documentation of this usage informa-
tion were excluded from pill burden analysis.
Study outcomes
Two primary outcomes were analysed: VF and emergence of NRTI resist-
ance, which was defined as the first detection of any major IAS-USA drug
resistance mutation19 to NRTI following VF. VF was defined as HIV-1 plasma
RNA level ≥400 copies/mL after 180 days of continuous treatment. If the
subsequent HIV-RNA was ,400 copies/mL, it was considered a viral blip
and not a VF. Not all patients experiencing VF had a genotypic resistance
test (GRT) performed following VF. Including subjects in the resistance ana-
lysis for whom we could not determine whether or not resistance had
emerged would potentially be incorrect because they would be included
as if they did not have any resistance. Thus, we first compared the charac-
teristics of those with and without GRT following VF within the same regi-
men group by the Wilcoxon rank-sum test. Variables tested were
treatment length, time from treatment initiation to VF, viral load at VF
and the consecutive viral load at VF. If there was no evidence for a difference
we excluded those with VF, but without GRT, from the resistance analysis.
Statistical methods
We analysed data with univariable and multivariable Cox proportional
hazards models to estimate HRs with 95% CIs and used robust standard
errors to account for possible intra-patient correlations because a patient
could be included twice: (i) first-line cART; and (ii) switched from first-line
cART while suppressed. Exposure time started at treatment initiation for
every treatment episode. Patients were censored at the time of death,
the last visit date or the end of the treatment, whichever came first.
Regimens were included categorically in the model.
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Adjustment comprised all variables with univariable significance, which
included age (continuous), ethnicity (white/non-white) and treatment
initiation year (continuous), and variables decided a priori, including baseline
HIV-RNA (log10 transformed, continuous) and baseline CD4 counts (square-
root transformed, continuous). Baseline CD4 and HIV-RNA data at the
initiation of the first cART were retrieved. Missing baseline CD4 (5%) and
HIV-RNA (7%) were imputed using multivariable normal regression (an
iterative Markov chain Monte Carlo method) and estimated by age, sex,
ethnicity, inclusion centre, transmission route and treatment initiation
year. In the pill burden analysis, models were adjusted for two more
co-variables: pill burden (i.e. the total pill number per day, continuous)
and the maximal dosing frequency per day (once/twice daily); both
were time-updated variables. Since CD4 counts or pill burden entered cat-
egorically did not improve the model fit, we treated them as continuous.
Collinearity was tested with variance inflation factors and correlation
matrices and none was found.
We performed two sensitivity analyses in which we either restricted
NNRTI drugs to efavirenz or our study population to patients on first-
line cART.
The analyses were performed using Stata 13.0 SE (StataCorp, TX, USA).
Results
Study population
Since 1996, 9755 patients have been ART-experienced in the SHCS.
Among these individuals, 2678 had initiated treatment containing
one of the regimens of interest and 1338 had switched from any
regimen to one of the regimens of interest. Ninety-nine (7%)
patients from the switching group were excluded due to VF or
drug resistance identified at switching. This resulted in 3917
treatment episodes from 3398 individuals. Baseline GRT was avail-
able for 2477/3398 (73%) patients. Resistance to the prescribed
regimen occurred in 77/3398 (2%) patients and these were
excluded. In total, our study comprised 3833 treatment episodes
from 3321 individuals (Figure 1). Baseline characteristics are sum-
marized in Table 1. Overall, differences among groups were
observed in all characteristics except for ethnicity.
VFs
The following numbers of VFs were observed for the different NRTI
backbones (Figure 2a and Table 1): tenofovir/emtricitabine,
19 failures from 1858 treatment episodes (1.0%); abacavir/
lamivudine, 9 from 387 (2.3%); tenofovir/lamivudine, 11 from
344 (3.2%); zidovudine/lamivudine, 45 from 1244 (3.6%).
In the univariable model the lowest failure rate was observed
for tenofovir/emtricitabine (as reference), followed by abacavir/
lamivudine [HR 2.38 (95% CI 1.07–5.26), P¼0.033], tenofovir/
lamivudine [HR 4.04 (1.92–8.48), P,0.001], zidovudine/lamivudine
[HR 3.89 (2.26–6.69), P,0.001] (Table 2, left part). After adjust-
ment for baseline CD4, baseline HIV-1 RNA and all significantly
associated co-variables, including age, ethnicity and treatment
initiation year, HRs among regimens decreased in magnitude
[abacavir/lamivudine, 2.01 (0.86 –4.55), P¼0.095; tenofovir/
lamivudine, 2.89 (1.22–6.88), P¼0.016; zidovudine/lamivudine,
2.28 (1.01 –5.14), P¼0.046]. Ethnicity was strongly asso-
ciated with treatment outcome: non-white patients were
2.67 times more likely to experience VF than white patients
(95% CI 1.69–4.23, P,0.001).
3833 treatment episodes from 3321 individuals
3917 treatment episodes from 3398 individuals
2678 initiated treatment containing one of
the regimens of interest
9755 ART-experienced patients enrolled in the SHCS
before 8 January 2013
1338 switched to one of the regimens of
interest
99 excluded due to identified VF
of drug resistance at switching
77 excluded due to resistance to the
prescribed regimen
Figure 1. Patient selection.
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Emergence of NRTI resistance
Next we analysed the relative efficacy of the four NRTI combinations
regarding time to the emergence of any NRTI resistance mutation fol-
lowing VF. However, 9 out of 19 (47%) failing regimens with tenofovir/
emtricitabine were not genotyped and the numbers of non-
genotyped treatments from failing treatments containing abacavir/
lamivudine, tenofovir/lamivudine and zidovudine/lamivudine,
respectively, were 4 out of 9 (44%), 1 out of 11 (9%) and 16 out of
45 (36%). The Wilcoxon rank-sum test did not find an indication of a
difference between patients with and without GRT following VF.
Because we had no alternative means to determine whether drug
resistance had developed in a non-genotyped failure episode, we
excluded those without GRT. After exclusion, we detected NRTI resist-
ance in 3 of 1849 (0.2%) tenofovir/emtricitabine-, 1 of 383 (0.3%)
abacavir/lamivudine-, 9 of 343 (2.6%) tenofovir/lamivudine- and 17
of 1228 (1.4%) zidovudine/lamivudine-containing treatment epi-
sodes (Figure 2b and Table 1).
In the univariable model the HR of abacavir/lamivudine
showed no evidence for an effect on the emergence of resistance
when compared with tenofovir/emtricitabine [1.72 (0.18–16.5),
P¼0.64], but NRTI resistance was more associated with tenofo-
vir/lamivudine [20.4 (5.49 –75.6), P,0.001] and zidovudine/
lamivudine [9.8 (2.88–33.3), P,0.001] (Table 3, left part). The
adjusted HR on emergence of NRTI resistance for patients on
tenofovir/lamivudine compared with tenofovir/emtricitabine was
11.3 (2.34–55.3, P¼0.003), but HR was not significantly different
for abacavir/lamivudine [1.17 (0.11–12.2), P¼0.90] or zidovu-
dine/lamivudine [4.02 (0.78 –20.7), P¼0.096]. Ethnicity was
strongly associated with the emergence of NRTI resistance [non-
white versus white, HR 4.43 (1.85 –10.6), P¼0.001] in both
univariable and multivariable analyses.
Study population in the pill burden analysis
Since pill number and dosing frequency were essential for the pill
burden analysis, patients without full documentation of tablet
usage were excluded, resulting in 3089 treatment episodes from
2685 individuals. Given that pill burden and dosing frequency are
time-updated variables, we had 4263 observations in total.
Median, minimal and maximal numbers of total pills of cART
were 2, 1 and 6, respectively. For the tenofovir/emtricitabine, aba-
cavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivu-
dine regimen groups, the median (IQR) number of total pills was
2 (1 –2), 2 (2 –3), 4 (4 –4) and 3 (3 –3), respectively, and the
Table 1. Baseline characteristics of study population
Treatment group
PaTDF/FTC ABC/3TC TDF/3TC ZDV/3TC
Patients (N¼3321), n (%) 1577 (47.5) 274 (8.3) 268 (8.1) 1202 (36.2)
Age at baseline (years), median (IQR) 40 (32–46) 40 (33–48) 39 (32–45) 37 (31–44) 0.001
Ethnicity, n (%) 0.142
white 1171 (74.2) 190 (69.3) 204 (76.1) 862 (71.7)
non-white 406 (25.8) 84 (30.7) 64 (23.9) 340 (28.3)
Gender and transmission route, n (%) 0.001
MSM 873 (55.4) 114 (41.6) 94 (35.1) 387 (32.2)
heterosexual men 314 (19.9) 67 (24.5) 63 (23.5) 285 (23.7)
heterosexual women 252 (16.0) 60 (21.9) 73 (27.2) 310 (25.8)
IVDU 69 (4.4) 18 (6.6) 29 (10.8) 157 (13.1)
unknown 69 (4.4) 15 (5.5) 9 (3.4) 63 (5.2)
CD4 count at baseline (cells/mm3), median (IQR) 282 (190–383) 250 (173–343) 200 (104–287) 208 (122–313) 0.001
Viral load at baseline (log10 copies/mL), median (IQR) 4.5 (3.5–5.0) 4.2 (2.6–4.9) 4.7 (3.6–5.3) 4.7 (3.9–5.3) 0.001
Treatment episodes (N¼3833), n (%) 1858 (48.5) 387 (10.1) 344 (9.0) 1244 (32.5)
Treatment initiation year, median (IQR) 2009 (2008–11) 2008 (2007–10) 2005 (2004–06) 2002 (2000–04) 0.001
First-line treatmentsb, n (%) 1292 (69.5) 198 (51.3) 211 (61.3) 912 (73.4) ,0.001
VFsc, n (%) 19 (1.0) 9 (2.3) 11 (3.2) 45 (3.6)
Failures without GRT, n 9 4 1 16
Resistance emergencec, n (%) 3 (0.2) 1 (0.3) 9 (2.6) 17 (1.4)
TDF, tenofovir; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; ZDV, zidovudine; IVDU, intravenous drug use.
aComparisons were made using the x2 test or the Kruskal–Wallis rank test.
bPercentage in parentheses indicates the ratio to the total number for that specific regimen.
cPercentage in parentheses refers to treatment episodes for the corresponding NRTI regimen.
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proportions of once-daily regimens were 97.2%, 92.5%, 81.0%
and 1.4%.
VFs in the pill burden analysis
Similar to the original analysis, the univariable analysis of pill bur-
den resulted in the lowest risk of having VF in the tenofovir/emtri-
citabine group when compared with the other three regimens
[abacavir/lamivudine, HR 2.15 (0.94–4.91), P¼0.069; tenofovir/
lamivudine, 4.29 (2.04–9.05), P,0.001; zidovudine/lamivudine,
2.89 (1.48–5.63), P¼0.002; Table 2, right part]. However, contrary
to the original analysis, in which pill burden and dosing frequency
were not adjusted for, the multivariable model did not show evi-
dence for differences among regimens [abacavir/lamivudine, HR
1.79 (0.76–4.23), P¼0.18; tenofovir/lamivudine, 2.64 (0.94–7.44),
P¼0.066; zidovudine/lamivudine, 3.10 (0.51–18.7), P¼0.22]. Pill
burden was associated with VF in both the univariable model
[HR 1.69 (1.31–2.19), P,0.001; Figure 3a] and the multivariable
model [HR 1.41 (1.01–1.96), P¼0.043]. In addition, non-white
ethnicity [HR 2.85 (1.64 –4.96), P,0.001] remained a strong
predictor of having VF after adjustment. In contrast to pill burden,
we did not find an association of dosing frequency with VF after
adjustment [HR 0.64 (0.12–3.30), P¼0.59].
Emergence of NRTI resistance in the pill burden analysis
Results followed the same pattern as results on VF in the pill bur-
den analysis. Evidence for effects of tenofovir/lamivudine and
zidovudine/lamivudine in the univariable model [abacavir/lamivu-
dine, HR 1.74 (0.18–16.7), P¼0.63; tenofovir/lamivudine, 21.0
(5.63–78.0), P,0.001; zidovudine/lamivudine, 5.84 (1.42–24.1),
P¼0.015; Table 3, right part] was not found after adjustment
[abacavir/lamivudine, HR 1.16 (0.10–12.9), P¼0.91; tenofovir/
lamivudine, 5.60 (0.71–44.0), P¼0.10; zidovudine/lamivudine,
1.62 (0.19–14.1), P¼0.66; Table 3, right part], but non-white eth-
nicity remained a strong risk factor [HR 3.54 (1.20 –10.4),
P¼0.022]. At the same time, we observed a significant effect of
pill burden in the univariable model [HR 2.83 (1.95 –4.10),
P,0.001; Figure 3b] and a trend in the multivariable model
[HR 1.72 (0.97– 3.02), P¼0.062]. Dosing frequency, however,
showed no effect on the emergence of NRTI resistance [HR 1.19
(0.24–5.82), P¼0.83].
Sensitivity analyses
Sensitivity analyses, in which we restricted NNRTI to efavirenz or
our study population to patients on first-line treatment only,
robustly showed qualitatively similar results. After adjusting add-
itionally for pill burden and dosing frequency, evidence for effects
of regimens both on VF and on the emergence of NRTI resistance
was not detected. However, one distinct exception was observed:
the abacavir/lamivudine treatment became a stronger predictor
of VF in the model restricted to first-line patients [HR, 2.93
(1.06–8.13), P¼0.039; pill burden analysis, HR 3.13 (1.10–8.87),
P¼0.032]. Pill burden was consistently observed to have an
impact [restricted to first-line patients on VF, HR 1.46 (1.01–2.13),
P¼0.046; on resistance, HR 2.25 (1.21–4.18), P¼0.011; restricted
to efavirenz on VF, HR 1.66 (1.17–2.37), P¼0.005; on resistance,
HR 2.14 (1.04–4.41), P¼0.038] and non-white ethnicity remained
strongly predictive of experiencing VF and emergence of NRTI
resistance when restricted to first-line patients [on VF, HR 2.66
(1.56– 4.51), P,0.001; on resistance, HR 3.32 (1.36 –8.15),
P¼0.009; in pill burden analysis on VF, HR 2.71 (1.41 –5.21),
P¼0.003; on resistance, HR 2.50 (0.76 –8.28), P¼0.13] and
restricted to efavirenz [on VF, HR 2.74 (1.67–4.47), P,0.001; on
resistance, HR 5.52 (2.01–15.2), P¼0.001; in pill burden analysis
on VF, HR 3.17 (1.72 –5.85), P,0.001; on resistance, HR 4.89
(1.25–19.2), P¼0.023].
Discussion
In this study, we compared VF rates and emergence of NRTI resist-
ance for the four major NRTI combinations tenofovir/emtricita-
bine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/
lamivudine combined with either efavirenz or nevirapine in a real-
world clinical setting. Treatment failure rates and frequency of
resistance emergence was remarkably low: failure frequencies
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Figure 2. Kaplan–Meier curves for time to (a) VF and (b) emergence of NRTI
resistance in the different treatment groups. The numbers of failure events
are shown in parentheses. TDF, tenofovir; FTC, emtricitabine; ABC, abacavir;
3TC, lamivudine; ZDV, zidovudine.
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ranged from 1.0% for the tenofovir/emtricitabine to 3.6% for the
zidovudine/lamivudine treatment group and the rate of NRTI
resistance was even lower, ranging from 0.2% for tenofovir/emtri-
citabine to 2.6% for tenofovir/lamivudine. In univariable and mul-
tivariable analyses we found that abacavir/lamivudine-, tenofovir/
lamivudine- and zidovudine/lamivudine-containing regimens had
a.2-fold higher risk of leading to VF than tenofovir/emtricitabine-
containing regimens. Tenofovir/lamivudine was more often asso-
ciated with emergence of NRTI resistance than tenofovir/emtrici-
tabine. Not taking the pill burden into account, this may suggest
superiority of emtricitabine over lamivudine. Among regimens
other than tenofovir/emtricitabine, no clear superiority was
found. When adjusting for pill burden and dosing frequency, we
found that a higher number of pills, but not dosing frequency,
was associated with VF and emergence of NRTI resistance.
Additionally, a very strong predictor of VF and resistance emer-
gence was non-white ethnicity.
Our results are consistent with a recent meta-analysis showing
that lower pill burden was associated with viral suppression.20
Similarly, patients receiving Atripla (efavirenz/tenofovir/emtricitabine
as a single-tablet regimen) had a lower risk of selection for drug
resistance compared with patients receiving the same drug compo-
nents as separate tablets.21 On the other hand, a large and long-
term randomized trial found that twice-daily regimens containing
raltegravir performed at least as well as once-daily regimens,22 dem-
onstrating that, in addition to the convenience of taking a drug regi-
men, the tolerability of the regimen is also of great importance. In a
previous study from the SHCS a higher risk of VF on cART23 due to
inferior self-reported adherence23,24 in sub-Saharan African patients
was observed. Since white patients infected with non-B subtypes
showed improved virological outcomes in the SHCS,25 differences
in adherence, but not between subtypes, could possibly explain
the strong effect of ethnicity found in our analyses.
Our study included not only treatment-naive patients initiating
their first cART, but also patients switching from their first cART.
Several potential problems should be noted in this respect. The
first of these is that second-line patients started treatment with
fully suppressed HIV-1-RNA. As a result, the risk of developing
drug resistance could be smaller than for first-line patients
because failure during the time to achieve viral suppression was
not possible by definition. However, this was the case for all four
regimens and a potential bias is unlikely. Second, for patients
Table 2. Uni- and multivariable Cox proportional hazards analysis for VFa
VF VF in pill burden analysis
univariable multivariable univariable multivariable
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Regimen
TDF/FTC 1 1 1 1
ABC/3TC 2.38 1.07–5.26 0.033 2.01 0.86–4.55 0.095 2.15 0.94–4.91 0.069 1.79 0.76–4.23 0.18
TDF/3TC 4.04 1.92–8.48 ,0.001 2.89 1.22–6.88 0.016 4.29 2.04–9.05 ,0.001 2.64 0.94–7.44 0.066
ZDV/3TC 3.89 2.26–6.69 ,0.001 2.28 1.01–5.14 0.046 2.89 1.48–5.63 0.002 3.10 0.51–18.7 0.22
Age, increase per year 0.97 0.95–0.99 0.005 0.99 0.96–1.01 0.23 0.98 0.96–1.01 0.22 1.00 0.97–1.03 0.95
Ethnicity
white 1 1 1 1
non-white 2.94 1.91–4.53 ,0.001 2.67 1.69–4.23 ,0.001 2.90 1.70–4.97 ,0.001 2.85 1.64–4.96 ,0.001
Gender and transmission route
MSM 1 — 1 —
heterosexual men 2.23 1.28–3.88 0.005 — 2.21 1.16–4.19 0.015 —
heterosexual women 1.84 1.00–3.38 0.051 — 1.61 0.76–3.40 0.22 —
IVDU 2.24 1.04–4.83 0.040 — 1.24 0.37–4.21 0.73 —
unknown 2.72 1.11–6.68 0.029 — 2.06 0.61–7.02 0.25 —
Square root of CD4 count
(cells/mL)
0.95 0.91–0.99 0.023 0.97 0.92–1.02 0.30 0.95 0.90–0.99 0.03 0.97 0.92–1.03 0.35
Log10 viral load (copies/mL) 1.14 0.95–1.36 0.17 1.07 0.88–1.30 0.50 1.18 0.95–1.46 0.13 1.13 0.89–1.44 0.31
Treatment initiation year,
increase per year
0.87 0.82–0.92 ,0.001 0.94 0.85–1.04 0.22 0.90 0.83–0.97 0.005 1.05 0.93–1.19 0.40
Pill number per day — — 1.69 1.31–2.19 ,0.001 1.41 1.01–1.96 0.043
Dosing frequency per day — — 1.81 1.02–3.19 0.041 0.64 0.12–3.30 0.59
TDF, tenofovir; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; ZDV, zidovudine; IVDU, intravenous drug use.
aThe multivariable models were adjusted for all variables indicated, i.e. showing HR.
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whose NRTI backbone was identical in the first and the second
cART (i.e. only the third agent was changed), it was possible
that drug resistance had developed as minor variants during the
first cART, but was not detected. Thus, second-line treatment
might have failed sooner than first-line treatment. However, sen-
sitivity analyses including only first-line patients confirmed that
our results were robust, apart from the higher HR of abacavir/
lamivudine-containing regimens on VF. The higher failure rate
for abacavir/lamivudine-containing first-line treatments could
again point to a higher activity of emtricitabine compared with
lamivudine, but to definitely tease out the superiority of emtricita-
bine, studies with a larger sample size are needed in determining
the relative efficacies of these NRTI combinations.
The strength of this study was its representativeness, due to
the following facts: (i) patients’ HIV-1 viral loads are monitored
regularly at 3 month intervals; (ii) viral loads ≥500 copies/mL
are genotyped as routine clinical practice; and (iii) retrospective
sequencing was performed on available samples for every failed
treatment episode even for patients, who were not genotyped,
from earlier times. On the other hand, limitations of our study
were that failure events were not numerous enough to differenti-
ate between NRTI backbones more precisely. The pill burden
analysis showed that HRs of abacavir/lamivudine, tenofovir/
lamivudine and zidovudine/lamivudine compared with tenofo-
vir/emtricitabine for having VF and NRTI resistance were indeed
all above 1 but had very wide CIs. On this point, it was difficult
to determine whether power issues limited our ability to docu-
ment evidence of regimen effect from the pill burden analysis.
Studies with more individuals are needed to evaluate the relative
efficacies of the regimens and to disentangle the effects of pill
burden and type of regimen. However, even with our sample
size we could observe effects of pill burden and ethnicity. Hence,
our data suggested that both ethnicity and pill burden were at
least equally important as the substances themselves in affecting
treatment efficacy and had a decisive impact on VF and the emer-
gence of NRTI resistance.
In conclusion, although VF and the emergence of resistance
were very low in the population studied, tenofovir/emtricitabine
appeared to be superior to abacavir/lamivudine, tenofovir/lamiv-
udine and zidovudine/lamivudine. However, if pill burden and
Table 3. Uni- and multivariable Cox proportional hazards analysis for emergence of NRTI resistancea
NRTI resistance NRTI resistance in pill burden analysis
univariable multivariable univariable multivariable
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Regimen
TDF/FTC 1 1 1 1
ABC/3TC 1.72 0.18–16.5 0.64 1.17 0.11–12.2 0.90 1.74 0.18–16.7 0.63 1.16 0.10–12.9 0.91
TDF/3TC 20.4 5.49–75.6 ,0.001 11.3 2.34–55.3 0.003 21.0 5.63–78.0 ,0.001 5.60 0.71–44.0 0.10
ZDV/3TC 9.80 2.88–33.3 ,0.001 4.02 0.78–20.7 0.096 5.84 1.42–24.1 0.015 1.62 0.19–14.1 0.66
Age, increase per year 0.94 0.91–0.98 0.002 0.97 0.94–1.01 0.21 0.96 0.92–1.00 0.058 0.98 0.94–1.03 0.45
Ethnicity
white 1 1 1 1
non-white 5.41 2.55–11.5 ,0.001 4.43 1.85–10.6 0.001 3.84 1.51–9.78 0.005 3.54 1.20–10.4 0.022
Gender and transmission route
MSM 1 — 1 —
heterosexual men 2.85 1.15–7.10 0.024 — 2.98 0.95–9.36 0.061 —
heterosexual women 2.48 0.93–6.58 0.068 — 2.64 0.76–9.11 0.13 —
IVDU 0.76 0.09–6.11 0.80 — — — — —
unknown 2.76 0.58–13.0 0.20 — 2.43 0.28–21.0 0.42 —
Square root of CD4 count
(cells/mL)
0.88 0.83–0.94 ,0.001 0.88 0.81–0.96 0.002 0.88 0.81–0.94 ,0.001 0.89 0.80–1.00 0.042
Log10 viral load (copies/mL) 1.03 0.73–1.45 0.86 0.87 0.67–1.15 0.33 1.30 0.78–2.19 0.32 1.05 0.60–1.83 0.86
Treatment initiation year,
increase per year
0.81 0.75–0.87 ,0.001 0.91 0.78–1.06 0.23 0.79 0.73–0.86 ,0.001 0.98 0.78–1.24 0.90
Pill number per day — — 2.83 1.95–4.10 ,0.001 1.72 0.97–3.02 0.062
Dosing frequency per day — — 2.33 0.91–5.99 0.078 1.19 0.24–5.82 0.83
TDF, tenofovir; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; ZDV, zidovudine; IVDU, intravenous drug use.
aThe multivariable models were adjusted for all variables indicated, i.e. showing HR.
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ethnicity were included in the model these differences became
statistically non-significant, illustrating the multifactorial nature
of treatment response. Thus, our results indicate a superiority of
tenofovir/emtricitabine-containing regimens, but do not allow
definitive determination of whether this effect is caused by the
lower pill burden or the substances themselves. Finally, our find-
ings are relevant in the light of the upcoming availability of generic
drugs. Even when generics are available, the aim of minimizing
the pill burden should be maintained.
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